Another factor to be considered (as to the selection of valve) is the new and growing cohort of younger patients they are only not that long ago included in the TAVR operation in USA. For these patients, the key considerations will be durability, speed to recovery to pre-symptom level of fitness and innovations. This cohort will be the key driver of growth in market share for Anteris and the TAVR as a whole.
Not advice, DYOR!
Ann: DurAVR First In Human Patient 6 Month Study Follow Up, page-34
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |